Nuvation Bio earnings date
Want to see NUVB full AI Analyst Report?
Nuvation Bio (NUVB) Q3 2026 Earnings Report
NUVB Q3 2026 EPS Results
- Actual EPS
- -$0.12
- Consensus EPS
- -$0.12
- Beat/Miss
- Beat by +$0.00
- One Year Ago EPS
- -$0.16
NUVB Q3 2026 Revenue Results
- Actual Revenue
- $44.95M
- Expected Revenue
- $34.40M
- Beat/Miss
- Beat by +$10.55M
- YoY Revenue Growth
- +242.61%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Nuvation Bio's next earnings date is estimated for March 11, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive overall. IBTROZI delivered $45 million of quarterly revenue, 18% sequential U.S. product revenue growth, more than 60% first-line new-start share and leadership in total active ROS1 TKI patients. Safusidenib produced encouraging long-term clinical data, received Fast Track designation and advanced into a broader four-study development plan. The company also reported strong liquidity, international launches ahead of expectations and a path toward profitability. The principal challenges were a 15% decline in overall ROS1 new patient starts, a 25% decline in laboratory testing alerts, persistent testing and treatment gaps, a shrinking pool of early switch patients and lengthy timelines for some safusidenib readouts.
Management expects IBTROZI growth to continue “at around the same clip as we’ve seen in the past,” with gross-to-net deductions remaining “generally stable” at approximately 30% and “around this 30% gross to net” through the end of the year; Europe approval is expected in “the first half of next year,” potentially triggering an “approximately $30 million” milestone payment. Safusidenib enrollment is expected in all 4 studies “in the coming months,” with more specific enrollment and data-readout timing updates next year; at least 20 patients are expected to be enrolled this year in the Grade 3 oligodendroglioma study, providing “between 6- and 9-month follow-up” by June 2027, with responses generally occurring “between 6 months and 12 months,” while the Grade 3 oligodendroglioma and post-vorasidenib studies are expected to begin producing responses in 2027 and the randomized PFS studies are expected to read out in “2029 or so” or later. The DDC platform update remains on track “by the end of the year,” spending patterns are not expected to change materially for the remainder of the year, and the company continues to believe it has sufficient capital to reach profitability.
- Strong Quarterly Revenue GrowthThird-quarter total revenue was $45 million, including $27.5 million in IBTROZI net U.S. product revenue and $17.5 million in collaboration and license revenue. For the first nine months of 2026, total revenue was $159.9 million.
- IBTROZI U.S. Product Revenue Increased 18%IBTROZI net U.S. product revenue grew 18% sequentially to approximately $27.5 million in the third quarter.
- Growing IBTROZI Patient Base and Market ShareApproximately 160 new patients started IBTROZI during the quarter, about 65% in the first-line setting. IBTROZI held more than 60% share of first-line new patient starts and became the leading ROS1 TKI in total active patients across all lines of therapy.
- Strong Launch PerformanceFifteen months after launch, IBTROZI had approximately twice the cumulative patient starts of earlier-generation ROS1 TKI launches at comparable commercialization points, based on internal data and adjusted claims estimates.
- Differentiated Clinical ProfileIn TKI-naive patients in TRUST-I, IBTROZI demonstrated a 90% objective response rate, 50 months of median duration of response and 50 months of median progression-free survival, supported by 51 months of median patient follow-up. IBTROZI is the only brain-penetrant ROS1 treatment option described as having no CNS warning and precaution in its label.
- Real-World Treatment Persistence Tracking Clinical TrialsTreatment-related adverse events and time on therapy in the real-world first-line and second-line TKI-naive populations were reported to be tracking closely with the TRUST trials. Adverse-event-related discontinuations remained low and consistent with the trials.
- IBTROZI Commercial Program Reached Self-Sustaining Run RateManagement stated that IBTROZI reached a quarterly revenue run rate related to launch-related expenses that represents a self-sustaining commercial program on a stand-alone basis.
- International Partnerships Performing Ahead of ExpectationsChina and Japan launches were progressing ahead of expectations, with testing rates described as excellent in both markets. Milestone and royalty payments from these partnerships contributed $7.7 million to third-quarter revenue.
- Potential European MilestonePotential approval in Europe during the first half of next year would trigger an approximately $30 million milestone payment to Nuvation Bio under its partnership with Eisai.
- Safusidenib Received FDA Fast Track DesignationIn August, the FDA granted Fast Track designation to safusidenib for the treatment of IDH1-mutant glioma, which management described as supportive external validation of the unmet need and the program's potential development path.
- Encouraging Long-Term Safusidenib DataIn the Phase II J201 study of 27 chemotherapy- and radiotherapy-naive patients with Grade 2 IDH1-mutant glioma, median follow-up reached 39 months, centrally assessed objective response rate increased to 52% from 44% at 28 months, median progression-free survival had not been reached, and the 36-month progression-free survival rate was 79%. No new safety signals were observed with additional follow-up.
- Expanded Safusidenib Development PlanThe enhanced development plan includes four studies addressing all grades and risk groups in IDH1-mutant glioma. Two studies in Grade 3 oligodendroglioma and patients who progressed following vorasidenib evaluate objective response rate as a primary endpoint and tumor growth rate as a secondary endpoint, while the SIGMA study and a separate Grade 2 study use progression-free survival as the primary endpoint.
- Safusidenib Enrollment and Readout ProgressEnrollment in the SIGMA study, including its exploratory cohort, was described as on track, with enrollment in all four studies expected in the coming months. Management expects initial response data from the Grade 3 oligodendroglioma and post-vorasidenib studies beginning in 2027.
- Drug-Drug Conjugate Platform AdvancingNuvation Bio remained on track to provide an update on its drug-drug conjugate platform by the end of the year, including additional detail on plans to move the program into the clinic.
- Strong Liquidity and Path to ProfitabilityCash, cash equivalents and marketable securities totaled $663.4 million as of September 30, 2026, including proceeds from the convertible debt offering. Management stated that the current operating plan provides sufficient capital to reach profitability.
- Continued Investment Across the BusinessThird-quarter operating expenses were $75.2 million, including $32.7 million of R&D expenses and $42.6 million of SG&A expenses. Management said investments were focused primarily on the TRUST and safusidenib clinical programs, future development activities and IBTROZI commercialization, while maintaining disciplined capital allocation.
- Commercial Initiatives to Expand Testing and AccessThe company is pursuing quality-based initiatives to improve NGS testing, including RNA-based testing, support biomarker-informed treatment decisions, use laboratory alerts to prioritize outreach, strengthen network collaborations, and advance field training, omnichannel marketing and AI-enabled HCP engagement. A major community pathway recently reinforced IBTROZI as its primary first- and second-line ROS1 TKI choice.
- Opportunity to Expand the ROS1 TKI MarketClaims data showed that the number of patients actively receiving a ROS1 TKI increased materially year over year following IBTROZI's launch, even after the market pullback in the third quarter. Management identified earlier ROS1 fusion detection and increased use of targeted therapy instead of chemotherapy with or without immunotherapy as opportunities to expand the market.
NUVB Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 11, 2027 | 2026 (Q4) | -0.12- | -0.11 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.12-0.12 | -0.16 | 25.00% (+0.04) | |
| Aug 06, 2026 | 2026 (Q2) | -0.14-0.18 | -0.17 | -5.88% (-0.01) | |
| May 04, 2026 | 2026 (Q1) | -0.030.01 | -0.16 | 106.25% (+0.17) | |
| Mar 02, 2026 | 2025 (Q4) | -0.09-0.11 | -0.15 | 26.67% (+0.04) | |
| Nov 03, 2025 | 2025 (Q3) | -0.17-0.16 | -0.15 | -6.67% (-0.01) | |
| Aug 07, 2025 | 2025 (Q2) | -0.17-0.17 | -1.89 | 91.01% (+1.72) | |
| May 07, 2025 | 2025 (Q1) | -0.15-0.16 | -0.07 | -128.57% (-0.09) | |
| Mar 06, 2025 | 2024 (Q4) | -0.13-0.15 | -0.06 | -150.00% (-0.09) | |
| Nov 06, 2024 | 2024 (Q3) | -0.13-0.15 | -0.09 | -66.67% (-0.06) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

